Trial reportGastroenterology2005
Viral kinetics in hepatitis C or hepatitis C/human immunodeficiency virus-infected patients.
Trial report in Gastroenterology, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00008463 (A Prospective, Multicenter, Phase II/III, Open-Label, Controlled, Randomized Trial Evaluating the Efficacy, Safety, and Tolerability of Interferon-alfa-2a Plus Ribavirin Versus PEG-interferon-alfa-2a Plus Ribavirin for Chronic Hepatitis C Virus), which is not on this map. Cited by 26 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Prospective, Multicenter, Phase II/III, Open-Label, Controlled, Randomized Trial Evaluating the Efficacy, Safety, and Tolerability of Interferon-alfa-2a Plus Ribavirin Versus PEG-interferon-alfa-2a Plus Ribavirin for Chronic Hepatitis C Virus (HCV) Infection in Individuals Co-Infected With Human Immunodeficiency Virus-1 (HIV-1)
Who cites it
26 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- HCV Council--critical appraisal of data: recommendations for clinical practice in a rapidly evolving therapeutic landscape.Liver international : official journal of the International Association for the Study of the Liver · 2016Guideline
- Peginterferon plus ribavirin versus interferon plus ribavirin for chronic hepatitis C.The Cochrane database of systematic reviews · 2014Pooled it
- Antiviral treatment for chronic hepatitis C in patients with human immunodeficiency virus.The Cochrane database of systematic reviews · 2010Pooled it
- Antiretroviral therapy, interferon sensitivity, and virologic setpoint in human immunodeficiency virus/hepatitis C virus coinfected patients.Hepatology (Baltimore, Md.) · 2014Trial
- Patterns and characteristics of hepatitis C transmission clusters among HIV-positive and HIV-negative individuals in the Australian trial in acute hepatitis C.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2011Trial
- Hepatitis C viral kinetics during treatment with peg IFN-alpha-2b in HIV/HCV coinfected patients as a function of baseline CD4+ T-cell counts.Journal of acquired immune deficiency syndromes (1999) · 2009Trial
- Estimation of dynamical model parameters taking into account undetectable marker values.BMC medical research methodology · 2006Trial
- Extended therapy with pegylated interferon and weight-based ribavirin for HCV-HIV coinfected patients.HIV clinical trialsTrial
- Diagnostic Utility of Pre-Genomic Hepatitis B RNA in the Evaluation of HBV/HIV Coinfection.Pathogens & immunity · 2024Article
- HIV influences clustering and intracellular replication of hepatitis C virus.Journal of viral hepatitis · 2021Article
- Detection and analysis of hepatitis C virus in HIV-infected patients in the Guangxi province of China.Experimental and therapeutic medicine · 2017Article
- Article
- Hepatitis C in human immunodeficiency virus co-infected individuals: Is this still a "special population"?World journal of hepatology · 2015Review
- National Trend and Characteristics of Acute Hepatitis C among HIV-Infected Individuals: A Matched Case-Control Study-Taiwan, 2001-2014.PloS one · 2015Article
- Modulation of HCV replication after combination antiretroviral therapy in HCV/HIV co-infected patients.Science translational medicine · 2014Article
- Analysis of hepatitis C virus decline during treatment with the protease inhibitor danoprevir using a multiscale model.PLoS computational biology · 2013Article
- HIV coinfection with hepatitis C virus: evolving epidemiology and treatment paradigms.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2012Review
- A perspective on modelling hepatitis C virus infection.Journal of viral hepatitis · 2010Review
- Hepatitis C virus (HCV) quasispecies complexity and selection in HCV/HIV-coinfected subjects treated with interferon-based regimens.The Journal of infectious diseases · 2010Article
- Pegylated interferon and ribavirin promote early evolution of nonstructural 5A protein in individuals with hepatitis C who demonstrate a response to treatment.The Journal of infectious diseases · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
BACKGROUND AND
aimsKinetic modeling of hepatitis C virus (HCV) response to interferon (IFN)-based therapy provides insights into factors associated with treatment outcomes. HCV/human immunodeficiency virus (HIV)-co-infected patients show lower response rates vs. HCV-monoinfected patients. Reasons for this remain unclear. This study evaluated kinetic parameters and treatment responses in co-infected vs monoinfected patients.
methodsCo-infected patients were randomized within a US multicenter trial (ACTG 5071) to receive pegylated-interferon (PEG-IFN) alfa-2a + ribavirin vs. IFN alfa-2a + ribavirin. Monoinfected controls were matched prospectively for treatment, genotype, age, sex, race, and histology. Quantitative HCV-RNA testing was performed at hours 0, 6, 12, 24, 48, and 72; days 7, 10, 14, 28, and 56; and weeks 12, 24, 48, and 72.
resultsTwelve HCV/HIV-co-infected and 15 HCV-monoinfected patients underwent viral kinetic sampling. Among HIV-positive patients the mean CD4(+) count was 325 cells/mm(3). Seventy-five percent of patients were genotype 1. The HCV-RNA level was undetectable at 72 weeks in 25% and 40% of co-infected and monoinfected patients, respectively. Phase 1/2 declines, free virus clearance rate, and infected hepatocyte death rate were not affected by co-infection status but differed by treatment. Efficiency (epsilon) > or = 90% at 60 hours was associated with viral clearance ( P = .02). Modeling with pooled parameters suggests baseline viral load is a key factor in time to response in this cohort. Predicted clearance time increased by 28% in co-infected patients.
conclusionsCo-infection status did not affect key kinetic parameters. Among kinetic parameters, efficiency was associated significantly with viral clearance. Co-infected patients may require longer treatment duration than monoinfected patients given their generally higher baseline viral loads.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.